152 filings
8-K
ZSANQ
Zosano Pharma Corp
3 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:01am
8-K
ZSANQ
Zosano Pharma Corp
2 Jun 22
Termination of a Material Definitive Agreement
8:35am
8-K
ZSANQ
Zosano Pharma Corp
18 May 22
Departure of Directors or Certain Officers
8:00am
8-K
ZSANQ
Zosano Pharma Corp
13 May 22
Zosano Pharma Reports First Quarter 2022 Financial Results
4:06pm
8-K
ZSANQ
Zosano Pharma Corp
5 May 22
Departure of Directors or Certain Officers
12:00am
8-K
90v4w7p85s
29 Apr 22
Zosano Pharma Provides Corporate Update
4:52pm
8-K
9jmt4fo8w u6bov8
11 Apr 22
Zosano Pharma Announces Reverse Stock Split Effective Today
4:08pm
8-K
ax07pbc
17 Mar 22
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:07pm
8-K
8avds6n9nc5xx4q8 qy
18 Feb 22
Other Events
5:11pm
8-K
vrzb5lf542csv96fwlo
9 Feb 22
Entry into a Material Definitive Agreement
5:21pm
8-K
9m7dzj2gjm
31 Jan 22
Other Events
9:45am
8-K
l51trsphld
24 Jan 22
Other Events
8:20am
8-K
d7r hd9bml
5 Jan 22
Other Events
9:22am
8-K
t30pkg69b4
13 Dec 21
Departure of Directors or Certain Officers
4:32pm
8-K
18dv822x
30 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
jtewor4 r3r
17 Nov 21
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
8:02am
8-K
70p5lcv8y s4kmxv
10 Nov 21
Zosano Pharma Reports Third Quarter 2021 Financial Results
4:18pm
8-K
26ej bzelyegf
29 Oct 21
Other Events
5:13pm
8-K
7rr3oi
6 Oct 21
Departure of Directors or Certain Officers
4:21pm
8-K
ce9km
4 Oct 21
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
8:10am